

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on Sept. 4, 2002

FULBRIGHT & JAWORSKI L.L.P.

By Dawn Olds



03c
LUD 5684.2 CIP (10106926) - JEL/NDH

#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : RENAULD, et al.
Serial No. : 09/919,162
Filed : July 31, 2001
For : ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE A SOLUBLE IL-TIF RECEPTOR OR BINDING PROTEIN WHICH BINDS TO IL-TIF/IL-22, AND USES THEREOF
Art Unit : UNKNOWN
Examiner : UNKNOWN

September 4, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

**INFORMATION DISCLOSURE
STATEMENT (37 CFR § 1.56, § 1.97 (c))**

SIR:

In accordance with their duty of disclosure, applicants wish to make the accompanying references of record in this application. These references were all cited in a PCT application which is a continuation in part of the subject application.

A copy of the International Search Report is attached as well. Note that none of the references were deemed to be "X" or "Y" references.

I. International Applications

WO 02/12345 (Kindsvogel, et al.), ZymoGenetics, published February 14, 2002.

WO 01/40467 (Presnell, et al.), ZymoGenetics, published December 1, 2000.

WO 00/55204 (Shi, et al.), Human Genome Sciences, Inc., published September 21, 2000.

WO 00/24758 (Dumoutier, et al.), Ludwig Institute for Cancer Research, published May 4, 2000.
WO 99/61617 (Ruben, et al.), Human Genome Sciences, Inc., published December 2, 1999.
WO 99/07848 (Lok, et al.), ZymoGenetics, Inc., published February 18, 1999.
WO 98/02542 (Petska, et al.), University of Medicine and Dentistry of New Jersey, published January 22, 1998.

II. European Patent Applications

EP 1191035 (Weiss, et al.), Schering Aktiengesellschaft, published August 24, 2001.

III. Journal Articles

Dumoutier, et al., "Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10 Related T Cell-Derived Inducible Factor/IL-22," *J. Immunol* 766:7090-7095 (2001).

Gruenberg, et al., "A soluble homologue of the human IL-10 receptor with preferential expression in placenta," *Genes & Immunity* 2:329-334 (2001).

Kotenko, et al., "Identification of the Functional interleukin-22 (IL-22) Receptor Complex," *J.Biol. Chem.* 276(4):2725-2732 (2001).

Kotenko, et al., "Identification, Cloning and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity," *J. Immunol* 166:7096-7103 (2001).

Xu, et al., "A soluble Class II Cytokine Receptor, IL-22 RA2, is a Naturally Occurring IL-22 antagonist," *Proc. Natl. Acad. Sci. USA* 98(17):9511-9516 (2001).

Xie, et al., "Interleukin (IL)-22, A Novel Human Cytokine That Signals Through The Interferon Receptor Related Proteins CRF2-4 and IL-22R," *J. Biol. Chem.* 275(40):31335-31339 (2000).

Opal, et al., "Impact of Basic Research on Tomorrow's Medicine," *CHEST* 117:1162-1172 (2000).

Kotenko, et al., "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes," *Oncogene* 19:2557-2565 (2000).

Dumoutier, et al., "Human interleukin-10 related T cell derived inducible factor: Molecular Cloning and Functional Characterization As An Hepatocyte Stimulating Factor," *Proc. Natl. Acad. Sci. USA* 97(18):10144-10149 (2000).

Fernandez-Botran, "Soluble Cytokine Receptors: Basic Immunology and Clinical Applications," Critical Reviews in Clinical Laboratory Sciences 36(3):165-224 (1999).

Kotenko, et al., "Identification and Functional Characterization of a Second Chain of the Interleukin-10 Receptor Complex," EMBOJ 16(19):5894-5903 (1997).

Meagher, et al., "Assay For Measuring Soluble Cellular Adhesion Molecules and Soluble Cytokine Receptors," J. Immunol Meth. 191:97-112 (1996).

Heaney, et al., "Soluble Cytokine Receptors," Blood 87(3):847-857 (1996).


IV. Other

EMBL Online: Accession No. AL050337 (May 26, 1999).


It is believed that the claims are patentable over these references, and a holding to that end is urged.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3100

Form PTO-1449 (Modified) (Rev. 11/92)	U.S. Dept. of Commerce Patent and Trademark Office	ATTY. DOCKET NO.	SERIAL NO.
		LUD-5684.2 CIP	09/919,162
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>		APPLICANT	
(Use several sheets if necessary)		RENAULD, et al.	
(37 CFR 1.98(b))		FILING DATE	GROUP
		July 31, 2001	UNKNOWN

U.S. PATENT DOCUMENTS

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
/	02/12345 /	02/14/02	WO				
/	01/40467 /	01/12/01	WO				
/	00/55204 /	09/21/00	WO				
*	00/24578 ?	05/04/00	WO				
/	99/61617 /	12/02/99	WO				

OTHER DOCUMENTS

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


	<input checked="" type="checkbox"/>	Dumoutier, et al., "Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10 Related T Cell-Derived Inducible Factor/IL-22," <i>J. Immunol.</i> 766:7090-7095 (2001)
	<input checked="" type="checkbox"/>	Gruenberg, et al., "A soluble homologue of the human IL-10 receptor with preferential expression in placenta," <i>Genes & Immunity</i> 2:329-334 (2001).
	<input checked="" type="checkbox"/>	Kotenko, et al., "Identification of the Functional interleukin-22 (IL-22) Receptor Complex," <i>J. Biol. Chem.</i> 276(4):2725-2732 (2001).
	<input checked="" type="checkbox"/>	Kotenko, et al., "Identification, Cloning and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity," <i>J. Immunol.</i> 166:7096-7103 (2001).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) (Rev. 11/92)	U.S. Dept. of Commerce Patent and Trademark Office	ATTY. DOCKET NO. LUD-5684.2 CIP	SERIAL NO. 09/919,162
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT RENAULD, et al.	
(37 CFR 1.98(b))		FILING DATE July 31, 2001	GROUP UNKNOWN



FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
/	99/07848 /	02/18/99	WO				
/	98/02542 /	01/22/98	WO				
/	11910357 /	08/24/01	EP				

OTHER DOCUMENTS

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

/	Xu, et al., "A soluble Class II Cytokine Receptor, IL-22 RA2, is a Naturally Occurring IL-22 antagonist," Proc. Natl. Acad. Sci. USA 98(17):9511-9516 (2001).
/	Xie, et al., "Interleukin (IL-22), a Novel Human Cytokine That Signals Through the Interleukin Receptor-related proteins CRF 2-4 and IL-22R," J. Biol. Chem. 275(40):31335-31339 (2000)
/	Opal, et al., "Impact of Basic Research on Tomorrow's Medicine," CHEST 117:1162-1172 (2000).
/	Kotenko, et al., "Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes," Oncogene 19:2557-2565 (2000).
/	Dumontier, et al., "Human interleukin-10 related T cell derived inducible factor: Molecular Cloning and Functional Characterization A An Hepatocyte Stimulating Factor," Proc. Natl. Acad. Sci. USA 97(18):10144-10149 (2000).
/	Fernandez-Botran, "Soluble Cytokine Receptors: Basic Immunology and Clinical Applications," Critical Reviews in Clinical Laboratory Sciences 36(3):165-224 (1999).
/	Kotenko, et al., "Identification and Functional Characterization of a Second Chain of the Interleukin-10 Receptor Complex," EMBOJ 16(19):5894-5903 (1997).
/	Meagher, et al., "Assay For Measuring Soluble Cellular Adhesion Molecules and Soluble Cytokine Receptors," J. Immunol Meth. 191:97-112 (1996).
/	Heaney, et al., "Soluble Cytokine Receptors," Blood 87(3):847-857 (1996).
/	EMBL Online: Accession No. AL050337 (May 26, 1999).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.